Five patients used PD-1 inhibitors for different types of de novo malignancies: 2 for melanoma, 1 for colon adenocarcinoma, 1 for malignant peripheral nerve sheath tumor (MPNST), and 1 for non-melanoma skin cancer. This evidence concerns the gene PDCD1 and colon adenocarcinoma.